This is a phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis. The purpose of this study is to see if we can prevent or delay the onset of lung disease in children with Cystic Fibrosis by giving them Azithromycin from when they are very young.

The study is funded by Cystic Fibrosis Foundation Therapeutics in the US and the sponsor for the study is Telethon Kids Institute. There are eight centres across Australia and New Zealand (Perth, Brisbane, Melbourne, Sydney, Adelaide and Auckland). Total of 130 participants have to be recruited for the study. The recruitment is still in progress for the study.

The children diagnosed with cystic fibrosis by New Born Screening can be enrolled in the study by six months of age. They will receive azithromycin or placebo thrice a week till the age of 3 years. There are 14 visits to the hospital with bronchoscopy at the first visit and then at the age of 1 ad 3 years and the CT scans are done at the age of 1 and 3 years.

For enquiries about the study please contact Julie Varghese on Julie.v@uq.edu.au or 07 3069 7444.